Valuation: Becton, Dickinson and Company

Market Cap 45.59B 39.63B 36.89B 33.87B 63.95B 4,352B 64.94B 435B 171B 2,167B 171B 167B 7,265B P/E 2026 *
36x
P/E 2027 * 23.5x
Enterprise Value 61.78B 53.71B 49.99B 45.9B 86.67B 5,898B 88.01B 589B 231B 2,936B 232B 227B 9,845B EV / Sales 2026 *
3.22x
EV / Sales 2027 * 3.01x
Free-Float
74.04%
Yield 2026 *
2.37%
Yield 2027 * 2.41%
1 day+0.19%
1 week+5.93%
Current month+13.81%
1 month+13.81%
3 months+13.40%
6 months-15.56%
Current year-14.06%
1 week 141.9
Extreme 141.9
144.35
1 month 131.25
Extreme 131.25
144.35
Current year 122.15
Extreme 122.15
179.95
1 year 122.15
Extreme 122.15
179.95
3 years 122.15
Extreme 122.15
263.5
5 years 122.15
Extreme 122.15
265.45
10 years 122.15
Extreme 122.15
265.45
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Compliance Officer - 2023-01-31
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%+5.93% - - 45.59B
-0.12%+2.15%-16.57%-5.43% 183B
-0.51%+2.10%-5.85%-3.19% 110B
+0.01%+0.46%+8.82%+66.57% 60.75B
+3.50%-0.66%+30.35%+55.04% 50.01B
-0.78%-0.23% - - 33.08B
+10.78%+15.25%+2.08%-33.81% 28.76B
+0.08%+3.31%+41.72%-7.87% 23.9B
-0.72%+7.03%+1.16%+1.58% 22.53B
-3.79%+7.69%-8.70%+2.42% 22.35B
Average +0.88%+4.38%+6.63%+9.41% 59.32B
Weighted average by Cap. +0.51%+5.37%-1.45%+8.75%

Financials

2026 *2027 *
Net sales 19.21B 16.7B 15.55B 14.27B 26.95B 1,834B 27.37B 183B 71.92B 913B 72.16B 70.57B 3,062B 19.72B 17.15B 15.96B 14.65B 27.67B 1,883B 28.1B 188B 73.83B 937B 74.07B 72.45B 3,143B
Net income 1.29B 1.12B 1.04B 958M 1.81B 123B 1.84B 12.3B 4.83B 61.29B 4.84B 4.74B 206B 1.98B 1.72B 1.6B 1.47B 2.77B 189B 2.81B 18.84B 7.39B 93.88B 7.42B 7.26B 315B
Net Debt 16.19B 14.08B 13.1B 12.03B 22.72B 1,546B 23.07B 154B 60.62B 770B 60.82B 59.48B 2,581B 13.82B 12.01B 11.18B 10.26B 19.38B 1,319B 19.68B 132B 51.72B 657B 51.89B 50.75B 2,202B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
72,000
Date Price Change Volume
26-07-29 143.00 +4.27% 79
26-07-24 €137.15 +1.59% 1
26-07-23 €135.00 +0.63% 66
26-07-22 €134.15 +0.07% 0
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
165.45USD
Average target price
180.25USD
Spread / Average Target
+8.95%

Quarterly revenue - Rate of surprise